[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646572":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":117,"collaborators":10,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":10,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":10,"enrollmentInfo":128,"targetDuration":10,"studyType":131,"phases":10,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":141,"whyStopped":10,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"ATTR-CM",null,"Participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM).",{"label":13,"type":10,"description":14,"interventionNames":10},"HF Control","Participants with guideline-directed medical therapy-directed heart failure and documentation within the past 2 years that either excludes transthyretin amyloid cardiomyopathy (ATTR-CM) or indicates a low probability of ATTR-CM.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[22,35,44,53,62,71,81,89,99,109],{"facility":23,"status":10,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"Research Site","Palo Alto","California","94305","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-122.14302,37.44188,{"lat":33,"lon":32},{"facility":23,"status":10,"city":36,"state":37,"zip":38,"country":27,"countryCode":28,"cosmosGeoPoint":39,"geoPoint":43,"contacts":10},"Chicago","Illinois","60611",{"type":30,"coordinates":40},[41,42],-87.65005,41.85003,{"lat":42,"lon":41},{"facility":23,"status":10,"city":45,"state":46,"zip":47,"country":27,"countryCode":28,"cosmosGeoPoint":48,"geoPoint":52,"contacts":10},"Boston","Massachusetts","02114",{"type":30,"coordinates":49},[50,51],-71.05977,42.35843,{"lat":51,"lon":50},{"facility":23,"status":10,"city":54,"state":55,"zip":56,"country":27,"countryCode":28,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"Portland","Oregon","97239-3098",{"type":30,"coordinates":58},[59,60],-122.67621,45.52345,{"lat":60,"lon":59},{"facility":23,"status":10,"city":63,"state":64,"zip":65,"country":27,"countryCode":28,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Germantown","Tennessee","38138",{"type":30,"coordinates":67},[68,69],-89.81009,35.08676,{"lat":69,"lon":68},{"facility":23,"status":10,"city":72,"state":10,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Essen","45147","Germany","DE",{"type":30,"coordinates":77},[78,79],7.01228,51.45657,{"lat":79,"lon":78},{"facility":23,"status":10,"city":82,"state":10,"zip":83,"country":74,"countryCode":75,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Würzburg","97078",{"type":30,"coordinates":85},[86,87],9.95121,49.79391,{"lat":87,"lon":86},{"facility":23,"status":10,"city":90,"state":10,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":10},"Guimarães","4835-044","Portugal","PT",{"type":30,"coordinates":95},[96,97],-8.29619,41.44443,{"lat":97,"lon":96},{"facility":23,"status":10,"city":100,"state":10,"zip":101,"country":102,"countryCode":103,"cosmosGeoPoint":104,"geoPoint":108,"contacts":10},"L'Hospitalet de Llobregat","08907","Spain","ES",{"type":30,"coordinates":105},[106,107],2.10028,41.35967,{"lat":107,"lon":106},{"facility":23,"status":10,"city":110,"state":10,"zip":111,"country":102,"countryCode":103,"cosmosGeoPoint":112,"geoPoint":116,"contacts":10},"Palma de Mallorca","07198",{"type":30,"coordinates":113},[114,115],2.65024,39.56939,{"lat":115,"lon":114},{"type":118,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100646572","retinal-fundus-imaging-and-oct-imaging-for-ocular-detection-of-attr-cm-100646572",false,"NCT07690436","Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM","A Multicenter Pilot Study to Investigate Ocular Involvement and the Potential of Ocular Imaging for Non-invasive Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","Inclusion Criteria:\n\n* 1\\. Participant must be 18 years and older at the time of signing the informed consent form.\n* 2\\. Participants with either of the following:\n* \\- Positive ATTR-CM cases: Participants with a clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) with amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining, or DPD-Tc, PYP-Tc, or HMDP-Tc scintigraphy with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio.\n* \\- Control population: Participants with a clinical diagnosis of guideline-directed medical therapy-directed heart failure (HF) and either:\n* a) Subgroup A: Definitively excluded ATTR-CM amyloidosis: negative cardiac or non-cardiac tissue biopsy for amyloid, or negative technetium scintigraphy within the past 2 years.\n* b) Subgroup B: Low probability of ATTR-CM amyloidosis, not definitively excluded: absence of amyloid-suggestive features on echocardiography (ECHO), electrocardiography (ECG), or cardiac magnetic resonance imaging (MRI) within the past 2 years, with documented clinical assessment indicating HF etiology unlikely attributable to amyloidosis; no amyloid-specific testing (technetium scintigraphy or biopsy) performed.\n* 3\\. Participant or legally authorized representative (LAR) must sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Any known eye condition that may preclude clear imaging of the retina.\n* 2\\. Any known history of amyloid light-chain (AL) amyloidosis.\n* 3\\. Any ocular surgery that, in the opinion of the investigator, makes participation in the study undesirable.\n* 4\\. Any medical condition that, in the opinion of the investigator, makes participation in the study undesirable, for example, if the participant is critically unwell or requires ongoing emergency treatment.\n* 5\\. Involvement in the planning and\u002For conduct of the study.\n* 6\\. In the opinion of the investigator, the participant is unlikely to comply with study procedures, restrictions, and requirements.\n* 7\\. Previous enrollment in the present study.","ALL","18 Years",{"count":129,"type":130},500,"ESTIMATED","OBSERVATIONAL","This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.",[134],"Transthyretin Amyloid Cardiomyopathy",[134,9,136,137,138,139,140],"Ocular Imaging","Heart Failure","Machine Learning","Optical coherence tomography","Retinal fundus imaging","NOT_YET_RECRUITING","2026-07-02",{"date":144,"type":145},"2026-07-08","ACTUAL",{"date":142,"type":130},{"date":148,"type":130},"2027-06-03",{"name":5,"class":6},10]